



## PRESS RELEASE

Madison, WI. – December 14, 2001

### **Bruker AXS Inc. Reports Product Revenue Growth in Second Quarter - Announces Initial Public Offering**

Bruker AXS Inc. (NASDAQ: BAXS) today announced that it has priced its initial public offering of 9,000,000 shares of common stock at a price of \$6.50 per share. The net proceeds from this offering are \$52,905,000, not including the underwriters' over-allotment. The shares will commence trading today on the NASDAQ National Market under the symbol "BAXS".

The company anticipates using net proceeds from the offering for general corporate purposes, including research and development, expansion of sales and marketing capabilities, working capital, strategic acquisitions, facilities expansion and repayment of long-term and short-term debt.

UBS Warburg LLC is bookrunning manager and, along with Thomas Weisel Partners LLC, co-lead manager of the offering. CIBC World Markets, SG Cowen and Robert W. Baird & Co. are the co-managers. Bruker AXS has granted the underwriters the option to purchase an aggregate of 1,350,000 additional shares to cover over-allotments, if any. A copy of the final prospectus may be obtained from the offices of UBS Warburg LLC, 299 Park Avenue, 41st Floor, New York, NY 10171.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the common stock of Bruker AXS, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Bruker AXS is a leading worldwide developer and provider of advanced X-ray systems which provide solutions for molecular and elemental analysis by X-ray crystallography, X-ray diffraction and X-ray fluorescence. Its integrated systems, which have particular application in the drug discovery and materials science fields, provide customers with high throughout capabilities to determine the structure of specific molecules, such as proteins, and to characterize and determine the composition of materials. Bruker AXS' substantial investment in research and development allows it to design, manufacture and market technologically innovative, integrated solutions to meet the rapidly growing needs of a diverse customer base, including biotechnology and pharmaceutical companies, semiconductor companies, raw materials manufacturers, chemical companies, academic institutions and other businesses involved in materials analysis.

For more information, please contact:

John Bourke  
CFO and Treasurer  
Bruker AXS Inc.  
5465 E. Cheryl Parkway  
Madison, WI 53711 (USA)  
Tel. (608) 276-3833  
Jbourke@bruker-axs.com